Risks
4 risks
Risk Intelligence
Global HIV funding cuts may impact ARV tender business
View Risks →Emcure Pharmaceuticals Limited — Q1 FY26
Emcure delivered a strong Q1 FY26 with revenue of ₹2,100 crore (+15.7% YoY), EBITDA of ₹404 crore (+20.1% YoY), and PAT of ₹215 crore (+41% YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Emcure delivered a strong Q1 FY26 with revenue of ₹2,100 crore (+15.7% YoY), EBITDA of ₹404 crore (+20.1% YoY), and PAT of ₹215 crore (+41% YoY). EBITDA margin expanded 70 bps to 19.2%, driven by operating leverage and product mix. Domestic business grew 9.4% (10.5% ex-FCM drag), while international grew 22%, led by emerging markets (+42%) and Canada (+16.4%). Management guided for 100 bps opex improvement and 50 bps gross margin expansion for FY26, with a 5-year vision to reach 23-24% EBITDA margins. Key growth drivers include the Sanofi diabetes portfolio (₹200 cr annualized), liposomal amphotericin B ramp-up in Europe, and new launches in derma/consumer wellness. Risk: US tariff uncertainty is minimal (exposure <3%), but global HIV funding cuts could pressure ARV tender business.
एमक्योर की पहली तिमाही (अप्रैल-जून 2025) की कमाई मजबूत रही। कंपनी ने ₹2,100 करोड़ का कारोबार किया, जो पिछले साल से 15.7% ज्यादा है। कमाई में से ₹404 करोड़ का मुनाफा (EBITDA) हुआ, जो 20.1% बढ़ा। शुद्ध मुनाफा (PAT) ₹215 करोड़ रहा, जो 41% ज्यादा है। कंपनी की मुनाफा दर (EBITDA मार्जिन) 19.2% हो गई, जो पिछले साल से 0.7% बेहतर है। इसकी वजह कम खर्च और बेहतर उत्पाद मिश्रण है। भारत में कारोबार 9.4% बढ़ा, जबकि अंतरराष्ट्रीय बाजार में 22% की बढ़त हुई। कंपनी का लक्ष्य इस साल मुनाफा दर को 23-24% तक ले जाना है। नए उत्पादों से उम्मीद है, जैसे डायबिटीज की दवा और यूरोप में एक खास दवा। अमेरिकी टैरिफ का असर बहुत कम है, लेकिन एचआईवी दवाओं के फंड में कटौती से कारोबार पर दबाव पड़ सकता है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Domestic Business Growth
9.4%
+9.4% YoY
India formulation grew 9.4% YoY to ₹995 crore; ex-FCM drag, growth was ~10.5%.
Emerging Markets Growth
42%
+42% YoY
Emerging markets revenue grew 42% YoY to ₹360 crore, driven by ARV and non-ARV segments.
Canada Business Growth
16.4%
+16.4% YoY
Canada grew 16.4% YoY to ₹342 crore, with momentum expected to sustain.
Gross Debt
₹700 crore
Flat QoQ
Gross debt stood at ~₹700 crore; expected to approach zero by FY26 end barring M&A.
Fast read
Guidance and risk preview
Management guided for 100 bps improvement in opex and 50 bps gross margin expansion, driven by productivity gains and product mix.
Management noted that US contributions to the Global Fund have been reduced, and PEPFAR funding is under pressure, which could affect ARV tender vo...
View Risks →